HC-056456 |
|||
| 531948 | MedKoo Biosciences | 10.0mg | EUR 120 |
HC-030031 |
|||
| B2100-10 | ApexBio | 10 mg | EUR 36 |
|
Description: TRPA1 channel blocker,potent and selective |
|||
HC-030031 |
|||
| B2100-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 44 |
|
Description: TRPA1 channel blocker,potent and selective |
|||
HC-030031 |
|||
| B2100-50 | ApexBio | 50 mg | EUR 100 |
|
Description: TRPA1 channel blocker,potent and selective |
|||
HC-030031 |
|||
| 522647 | MedKoo Biosciences | 10.0mg | EUR 250 |
HC-056456 |
|||
| HY-112729 | MedChemExpress | 25mg | EUR 362.4 |
HC-030031 |
|||
| HY-15064 | MedChemExpress | 100mg | EUR 357.6 |
HC-067047 |
|||
| HY-100208 | MedChemExpress | 10mg | EUR 224.4 |
HC-030031 |
|||
| SIH-303-10MG | Stressmarq | 10 mg | EUR 79 |
|
Description: TRPA1 blocker |
|||
HC-030031 |
|||
| SIH-303-50MG | Stressmarq | 50 mg | EUR 322 |
|
Description: TRPA1 blocker |
|||
HC-030031 |
|||
| T6530-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: HC-030031 |
|||
HC-030031 |
|||
| T6530-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: HC-030031 |
|||
HC-030031 |
|||
| T6530-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: HC-030031 |
|||
HC-030031 |
|||
| T6530-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: HC-030031 |
|||
HC-030031 |
|||
| T6530-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: HC-030031 |
|||
HC-056456 |
|||
| T4604-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: HC-056456 |
|||
HC-056456 |
|||
| T4604-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: HC-056456 |
|||
HC-056456 |
|||
| T4604-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: HC-056456 |
|||
HC-056456 |
|||
| T4604-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: HC-056456 |
|||
HC-056456 |
|||
| T4604-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: HC-056456 |
|||
HC-067047 |
|||
| T4680-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: HC-067047 |
|||
HC-067047 |
|||
| T4680-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: HC-067047 |
|||
HC-067047 |
|||
| T4680-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: HC-067047 |
|||
HC-067047 |
|||
| T4680-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: HC-067047 |
|||
HC-067047 |
|||
| T4680-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: HC-067047 |
|||
HC-030031 |
|||
| abx076575-25ml | Abbexa | 2.5 ml | EUR 225 |
HC-030031 |
|||
| abx076575-500l | Abbexa | 500 µl | EUR 118.75 |
HC-067047 |
|||
| abx282363-100g | Abbexa | 100 µg | Ask for price |
HC-067047 |
|||
| abx282363-20g | Abbexa | 20 µg | EUR 131.25 |
HC-067047 |
|||
| abx282363-50g | Abbexa | 50 µg | EUR 325 |
HC067047 Hydrochloride(883031-03-6 free base) |
|||
| T4680L-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: HC067047 Hydrochloride(883031-03-6 free base) |
|||
HC067047 Hydrochloride(883031-03-6 free base) |
|||
| T4680L-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: HC067047 Hydrochloride(883031-03-6 free base) |
|||
HC067047 Hydrochloride(883031-03-6 free base) |
|||
| T4680L-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: HC067047 Hydrochloride(883031-03-6 free base) |
|||
HC067047 Hydrochloride(883031-03-6 free base) |
|||
| T4680L-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: HC067047 Hydrochloride(883031-03-6 free base) |
|||
HC067047 Hydrochloride(883031-03-6 free base) |
|||
| T4680L-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: HC067047 Hydrochloride(883031-03-6 free base) |
|||
Roller Base (HC34, HC35 & VHC35) |
|||
| TW-R033-8C00 | MiTeGen | 1 UNIT | EUR 331 |
|
Description: Roller Base (HC34, HC35 & VHC35) |
|||
HC-070 |
|||
| HY-112302 | MedChemExpress | 5mg | EUR 542.4 |
HC-070 |
|||
| T15465-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: HC-070 |
|||
HC-070 |
|||
| T15465-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: HC-070 |
|||
HC-070 |
|||
| T15465-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: HC-070 |
|||
HC-070 |
|||
| T15465-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: HC-070 |
|||
HC-070 |
|||
| T15465-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: HC-070 |
|||
Cryo-Sentry Level Alarm (HC20 & HC34) |
|||
| TW-R034-8C15 | MiTeGen | 1 UNIT | EUR 1215 |
|
Description: Cryo-Sentry Level Alarm (HC20 & HC34) |
|||
BMS 599626 2HCl (873837-23-1(HCl)) |
|||
| T5398-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: BMS 599626 2HCl (873837-23-1(HCl)) |
|||
BMS 599626 2HCl (873837-23-1(HCl)) |
|||
| T5398-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: BMS 599626 2HCl (873837-23-1(HCl)) |
|||
BMS 599626 2HCl (873837-23-1(HCl)) |
|||
| T5398-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: BMS 599626 2HCl (873837-23-1(HCl)) |
|||
BMS 599626 2HCl (873837-23-1(HCl)) |
|||
| T5398-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: BMS 599626 2HCl (873837-23-1(HCl)) |
|||
BMS 599626 2HCl (873837-23-1(HCl)) |
|||
| T5398-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: BMS 599626 2HCl (873837-23-1(HCl)) |
|||
Anti-ZMAT4 (7H3-1C11) |
|||
| YF-MA19341 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to ZMAT4 |
|||
Anti-SNRPG (2H8-1C12) |
|||
| YF-MA15517 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to SNRPG |
|||
Anti-EIF2S1 (3H12-C11) |
|||
| YF-MA10267 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to EIF2S1 |
|||
Human Histone H3.2 (H3C15) ELISA Kit |
|||
| abx258161-1mg | Abbexa | 1 mg | EUR 6187.5 |
Human Histone H3.2 (H3C15) ELISA Kit |
|||
| abx258161-20g | Abbexa | 20 µg | EUR 3275 |
Human Histone H3.2 (H3C15) ELISA Kit |
|||
| abx258161-5g | Abbexa | 5 µg | EUR 687.5 |
H9c2 (2-1) |
|||
| ABC-TC0286 | AcceGen | 1 vial | Ask for price |
|
Description: Rat BDIX heart myoblast. Skeletal muscle properties. Myotubes formed at confluency respond to acetylcholine. Differentiation improved by reducing serum concentration to 1%. |
|||
HC11 |
|||
| C0006035 | Addexbio | One Frozen vial | EUR 470 |
Monoclonal CRY1 Antibody (clone 4H4-1C4), Clone: 4H4-1C4 |
|||
| APR11687G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A Monoclonal antibody against Human CRY1 (clone 4H4-1C4). The antibodies are raised in Mouse and are from clone 4H4-1C4. This antibody is applicable in WB and IHC-P, IF, E |
|||
anti-Nucleobindin 1 (1H8-2C11) |
|||
| LF-MA10212 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to Nucleobindin 1 |
|||
Hemagglutinin Antibody [4H1C10] |
|||
| PM-4006-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: Hemagglutinin Monoclonal Antibody: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. The more recent virulent strain of H5N1 is now seen in Africa and Europe, as well as in southeast Asia. There is some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. HA interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues. Virus isolated from a human infected with the H5N1 strain in 1997 could bind to oligosaccharides from human as well as avian sources, indicating its species-jumping ability. While efforts were made to use relatively conserved regions of the viral sequence as the antigen, the influenza virus genome has drifted somewhat from what was first reported. However, this antibody was able to recognize peptides derrived from viruses from Indonesian human patients infected in 2007. |
|||
Hemagglutinin Antibody [4H1C10] |
|||
| PM-4006-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: Hemagglutinin Monoclonal Antibody: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. The more recent virulent strain of H5N1 is now seen in Africa and Europe, as well as in southeast Asia. There is some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. HA interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues. Virus isolated from a human infected with the H5N1 strain in 1997 could bind to oligosaccharides from human as well as avian sources, indicating its species-jumping ability. While efforts were made to use relatively conserved regions of the viral sequence as the antigen, the influenza virus genome has drifted somewhat from what was first reported. However, this antibody was able to recognize peptides derrived from viruses from Indonesian human patients infected in 2007. |
|||